NASDAQ:ZVSAW

ZyVersa Therapeutics (ZVSAW) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
$0.06
$0.10
50-Day Range
$0.07
$0.07
52-Week Range
$0.04
$0.30
Volume
75,000 shs
Average Volume
27,909 shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

About ZyVersa Therapeutics

ZyVersa Therapeutics, Inc., a clinical stage biopharmaceutical company, develops and commercializes products for the treatment of renal and inflammatory diseases. It engages in the development of VAR 200, a cholesterol efflux mediator to treat focal segmental glomerulosclerosis, alport syndrome, and diabetic kidney disease; and IC 100, a novel inflammasome ASC inhibitor for treatment of multitude of inflammatory diseases. ZyVersa Therapeutics, Inc. is headquartered in Weston, Florida.

ZVSAW Stock News Headlines

See More Headlines
Receive ZVSAW Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ZyVersa Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
Current Symbol
NASDAQ:ZVSAW
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
N/A
10 Best Stocks to Own in 2024 Cover

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio.

Get This Free Report

Key Executives

  • Mr. Stephen C. Glover (Age 62)
    Co-Founder, CEO & Chairman
  • Mr. Peter Wolfe (Age 55)
    Chief Financial Officer
  • Mr. Nicholas A. LaBella Jr. (Age 66)
    MS, RPh., Chief Scientific Officer and Sr. VP of R&D
  • Ms. Melda Uzbil O'connell
    Sr. VP of Corp. Devel.
  • Ms. Karen A. Cashmere (Age 59)
    Chief Commercial Officer
  • Dr. Pablo A. Guzman FACC
    M.D., Chief Medical Officer & Member of Scientific Advisory Board

This page (NASDAQ:ZVSAW) was last updated on 4/26/2024 by MarketBeat.com Staff

From Our Partners